Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 7, 2014, Pages 812-824

  Staudinger, Benjamin J ^a   Muller, Jocelyn Fraga ^a   Halldórsson, Skarpheóinn ^b   Boles, Blaise ^c   Angermeyer, Angus ^a   Nguyen, Dao ^a   Rosen, Henry ^a   Baldursson, Ólafur ^b,d   Gottfreosson, Magnus ^b,d   Guomundsson, Guomundur Hrafn ^b   Singh, Pradeep K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c UNIVERSITY OF MICHIGAN   (United States)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Biofilm; Chronic infection; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LEUKOCYTE ELASTASE; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CYSTIC FIBROSIS; DISEASE ASSOCIATION; EVOLUTIONARY ADAPTATION; GEL; HOST RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY EPITHELIUM;

ANIMALS; BIOFILMS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG RESISTANCE, BACTERIAL; GENETIC MARKERS; HUMANS; LEUKOCYTE ELASTASE; MICE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; VIRULENCE;

EID: 84897445133     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201312-2142OC     Document Type: Article

References (74)

1. Gibson RL, Burns JL, Ramsey BW Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-951.
2. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60:539-574.
3. Ballow M, Notarangelo L, Grimbacher B., Cunningham-Rundles C, Stein M, Helbert M., Gathmann B, Kindle G, Knight AK, Ochs HD, et al. Immunodeficiencies. Clin Exp Immuno. 2009; 158:14-22.
4. Orange JS. Congenital immunodeficiencies and sepsis. Pediatr Crit Care Med 2005; 6:S99-S107.
5. Khan TZ, Wagener JS, Bost T, Martinez J., Accurso FJ, Riches DW Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075-1082.
6. Wagener JS, Kahn TZ, Copenhaver S.C., Accurso FJ Early inflammation and the development of pulmonary disease in cystic fibrosis. Pediatr Pulmonol Suppl 1997; 16:267-268.
7. Ramsey BW, Pepe MS, Quan J.M., Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman C.M., Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study group. N Engl J Med 1999; 340:23-30.
8. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M., Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847-856.
9. Tramper-Stranders G.A., van der Ent CK, Molin S, Yang L, Hansen SK, Rau MH, Ciofu O, Johansen HK, Wolfs TF. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clin Microbiol Infect 2012; 18:567-574.
10. Lam J, Chan R, Lam K., Costerton JW Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980; 28:546-556.
11. Hoiby N, Krogh Johansen H, Moser C, Song Z., Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3:23-35.
12. Singh PK, Schaefer AL, Parsek M.R., Moninger TO, Welsh MJ, Greenberg EP Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-764.
13. Bjarnsholt T, Jensen PO, Fiandaca M.J., Pedersen J., Hansen CR, Andersen CB, Pressler T, Givskov M., Hoiby N. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmono. 2009; 44:547-558.
14. Worlitzsch D, Tarran R, Ulrich M., Schwab U, Cekici A, Meyer K.C., Birrer P., Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317-325.
15. Sriramulu DD, Lunsdorf H, Lam J.S., Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol 2005; 54:667-676.
16. Bjarnsholt T, Alhede M, Alhede M., Eickhardt-Sorensen SR, Moser C, Kuhl M., Jensen PO, Hoiby N. The in vivo biofilm. Trends Microbiol 2013; 21:466-474.
17. Wilder CN, Allada G, Schuster M. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 2009; 77: 5631-5639.
18. Smith EE, Buckley DG, Wu Z, Saenphimmachak C., Hoffman LR, D'Argenio DA, Miller SI, Ramsey B.W., Speert DP, Moskowitz SM, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103: 8487-8492.
19. Hancock RE, Mutharia LM, Chan L, Darveau R.P., Speert DP, Pier GB Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide o side chains. Infect Immun 1983; 42:170-177.
20. Luzar MA, Thomassen MJ, Montie TC Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun 1985; 50: 577-582.
21. Mahenthiralingam E, Campbell ME, Speert DP Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596-605.
22. Lee B, Haagensen JA, Ciofu O, Andersen J.B., Hoiby N., Molin S. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 2005; 43:5247-5255.
23. Deligianni E, Pattison S, Berrar D., Ternan NG, Haylock RW, Moore JE, Elborn S.J., Dooley JS. Pseudomonas aeruginosa cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro. BMC Microbiol 2010; 10:38.
24. Rau MH, Hansen SK, Johansen H.K., Thomsen LE, Workman CT, Nielsen KF, Jelsbak L, Hoiby N., Yang L, Molin S. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 2010; 12:1643-1658.
25. Head NE, Yu H. Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect Immun 2004; 72:133-144.
26. Schaber JA, Carty NL, McDonald N.A., Graham ED, Cheluvappa R, Griswold JA, Hamood AN Analysis of quorum sensing-deficient clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 2004; 53:841-853.
27. Ciornei CD, Novikov A, Beloin C., Fitting C, Caroff M, Ghigo J.M., Cavaillon JM, Adib-Conquy M. Biofilm-forming Pseudomonas aeruginosa bacteria undergo lipopolysaccharide structural modifications and induce enhanced inflammatory cytokine response in human monocytes. Innate Immun 2010; 16:288-301.
28. Gursoy UK, Pollanen M, Kononen E., Uitto VJ Biofilm formation enhances the oxygen tolerance and invasiveness of Fusobacterium nucleatum in an oral mucosa culture model. J Periodontol 2010; 81:1084-1091.
29. Staudinger B, Muller JM, Halldórsson S, Angermeyer A, Boles BR, Baldursson O, Rosen H, Singh PK. CF sputum enhances the formation of Pseudomonas aeruginosa aggregates and promotes tolerance to antibiotics and host defenses. Pediatr Pulmono. 2010; 45:1-76.
30. Jacobs MA, Alwood A, Thaipisuttikul I., Spencer D, Haugen E, Ernst S., Will O, Kaul R, Raymond C, Levy R, et al. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2003; 100:14339-14344.
31. Hoang TT, Karkhoff-Schweizer RR, Kutchma A.J., Schweizer HP A broad-host-range flp-frt recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 1998; 212:77-86.
32. Matsui H, Wagner VE, Hill D.B., Schwab UE, Rogers TD, Button B, Taylor RM II, Superfine R, Rubinstein M, Iglewski BH, et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci USA 2006; 103:18131-18136.
33. O'Toole G.A., Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998; 30:295-304.
34. Drake D, Montie TC Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J Gen Microbiol 1988; 134:43-52.
35. Sonawane A, Jyot J, During R., Ramphal R. Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa. Infect Immun 2006; 74:6682-6689.
36. Halldorsson S, Asgrimsson V, Axelsson I., Gudmundsson GH, Steinarsdottir M, Baldursson O, Gudjonsson T. Differentiation potential of a basal epithelial cell line established from human bronchial explant. In Vitro Cell Dev Biol Anim 2007; 43:283-289.
37. Halldorsson S, Gudjonsson T, Gottfredsson M., Singh PK, Gudmundsson GH, Baldursson O. Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 2010; 42:62-68.
38. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372:415-417.
39. Mall M, Grubb BR, Harkema J.R., O'Neal WK, Boucher RC Increased airway epithelial Na1 absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10:487-493.
40. Matsui H, Grubb BR, Tarran R, Randell S.H., Gatzy JT, Davis CW, Boucher RC Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95:1005-1015.
41. Barasch J, Kiss B, Prince A., Saiman L, Gruenert D, al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991; 352:70-73.
42. Zhang Y, Doranz B, Yankaskas J.R., Engelhardt JF Genotypic analysis of respiratory mucous sulfation defects in cystic fibrosis. J Clin Invest 1995; 96:2997-3004.
43. Pier GB, Grout M, Zaidi TS Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 94:12088-12093.
44. Painter RG, Bonvillain RW, Valentine V.G., Lombard GA, LaPlace SG, Nauseef WM, Wang G. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J Leukoc Biol 2008; 83:1345-1353.
45. Di A, Brown ME, Deriy L.V., Li C., Szeto FL, Chen Y, Huang P, Tong J., Naren AP, Bindokas V, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8:933-944.
46. Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialogm1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993; 92:1875-1880.
47. Smith JJ, Travis S, Greenberg E.P., Welsh MJ Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229-236.
48. Pezzulo AA, Tang XX, Hoegger M.J., Alaiwa MH, Ramachandran S, Moninger TO, Karp P.H., Wohlford-Lenane CL, Haagsman HP, van Eijk M, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487:109-113.
49. Bonfield TL, Konstan MW, Burfeind P, Panuska J.R., Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13:257-261.
50. Weber AJ, Soong G, Bryan R., Saba S, Prince A. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281:L71-L78.
51. Eidelman O, Srivastava M, Zhang J., Leighton X, Murtie J, Jozwik C., Jacobson K, Weinstein DL, Metcalf EL, Pollard HB. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alpha/NFkappaB pathway. Mol Med 2001; 7: 523-534.
52. Accurso FJ. Early pulmonary disease in cystic fibrosis. Curr Opin Pulm Med 1997; 3:400-403.
53. Pillarisetti N, Williamson E, Linnane B., Skoric B, Robertson CF, Robinson P, Massie J., Hall GL, Sly P, Stick S, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75-81.
54. Armstrong DS, Grimwood K, Carlin J.B., Carzino R., Gutierrez JP, Hull J, Olinsky A, Phelan E.M., Robertson CF, Phelan PD. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197-1204.
55. Jyot J, Sonawane A, Wu W., Ramphal R. Genetic mechanisms involved in the repression of flagellar assembly by Pseudomonas aeruginosa in human mucus. Mol Microbiol 2007; 63:1026-1038.
56. Palmer KL, Mashburn LM, Singh P.K., Whiteley M. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 2005; 187:5267-5277.
57. Wolfgang MC, Jyot J, Goodman A.L., Ramphal R., Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients 10. 1073/ pnas.0307553101. Proc Natl Acad Sci USA 2004; 101:6664-6668.
58. Lopez-Boado Y.S., Espinola M, Bahr S., Belaaouaj A. Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity. J Immuno. 2004; 172:509-515.
59. Flume PA, O'Sullivan BP, Robinson KA, Goss C.H., Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J., Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
60. Alhede M, Kragh KN, Qvortrup K, Allesen-Holm M, van Gennip M, Christensen LD, Jensen P.O., Nielsen AK, Parsek M, Wozniak D, et al. Phenotypes of non-attached pseudomonas aeruginosa aggregates resemble surface attached biofilm. PloS ONE 2011; 6:e27943.
61. Sauer K, Camper AK, Ehrlich G.D., Costerton JW, Davies DG Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184:1140-1154.
62. Ramsey MM, Whiteley M. Pseudomonas aeruginosa attachment and biofilm development in dynamic environments. Mol Microbiol 2004; 53:1075-1087.
63. Davies DG, Parsek MR, Pearson J.P., Iglewski BH, Costerton JW, Greenberg EP The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280:295-298.
64. Parkins MD, Ceri H, Storey DG Pseudomonas aeruginosa gaca, a factor in multihost virulence, is also essential for biofilm formation. Mol Microbiol 2001; 40:1215-1226.
65. Banin E, Vasil ML, Greenberg EP Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA 2005; 102:11076-11081.
66. Jackson KD, Starkey M, Kremer S., Parsek MR, Wozniak DJ Identification of PSL, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol 2004; 186:4466-4475.
67. Colvin KM, Gordon VD, Murakami K, Borlee B.R., Wozniak DJ, Wong GC, Parsek MR The PEL polysaccharide can serve a structural and protective role in the biofilm matrix of Pseudomonas aeruginosa. PLoS Pathog 2011; 7:e1001264.
68. Nguyen D, Joshi-Datar A, Lepine F., Bauerle E, Olakanmi O, Beer K., McKay G, Siehnel R, Schafhauser J, Wang Y, et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 2011; 334:982-986.
69. Zhao G, Hochwalt PC, Usui M.L., Underwood RA, Singh PK, James GA, Stewart P.S., Fleckman P., Olerud JE. Delayed wound healing in diabetic (db/db) mice with Pseudomonas aeruginosa biofilm challenge: a model for the study of chronic wounds. Wound Repair Regen 2010; 18:467-477.
70. Sagel SD, Sontag MK, Accurso FJ Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. Pediatr Pulmono. 2009; 44:402-409.
71. Taylor RF, Morgan DW, Nicholson P.S., Mackay IS, Hodson ME, Pitt TL Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Thorax 1992; 47:426-428.
72. Hansen SK, Rau MH, Johansen H.K., Ciofu O., Jelsbak L, Yang L, Folkesson A., Jarmer HO, Aanaes K, von Buchwald C, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012; 6:31-45.
73. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B., Burns JL Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-1502.
74. Stewart PS, Franklin MJ Physiological heterogeneity in biofilms. Nat Rev Microbiol 2008; 6:199-210.